Item 8.01 Other Events.

On September 29, 2020, CTI BioPharma Corp. (the "Company") issued a press release announcing the Company's plans to submit a new drug application seeking FDA approval of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.






  (d) Exhibits




Exhibit     Description

99.1          Press release dated September 29, 2020

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses